ASCO GI Conference Coverage

Biomarkers Identified for Celecoxib Chemoprevention in CRC

(Medscape Medical News) Jan 26, 2017 - Most cases of colorectal cancer are preceded by adenomas. Data show that chemoprevention with selective cyclooxygenase-2 (COX-2) inhibitors, particularly celecoxib (Celebrex, GD Searle), can reduce the incidence of these lesions.

read article (free registration required)

Overall Survival Benefit For Resminostat In First-line Liver Cancer Study Subgroup

(4SC AG) Jan 24, 2017 - 4SC AG today announced that the study investigators presented the detailed scientific study analysis (abstract #252) from the multi-center, randomized, 170 patient Phase II study conducted by 4SC’s cooperation partner Yakult Honsha Co., Ltd. (Yakult Honsha) in Japan and South Korea at the 2017 Gastrointestinal Cancers Symposium in San Francisco, USA.

read corporate press release

Cabozantinib for Carcinoid and Pancreatic NETs: ‘Encouraging'

(Medscape Medical News) Jan 25, 2017 - Treatment with cabozantinib (Cometriq, Exelixis) has shown promising objective tumor responses and progression-free survival in patients with advanced carcinoid and pancreatic neuroendocrine tumors (pNETs), according to findings presented here at the Gastrointestinal Cancers Symposium (GICS) 2017.

read article (free registration required)

Combination Boosts PFS in Mutated CRC

(MedPage Today) Jan 24, 2017 - Progression-free survival (PFS) more than doubled in BRAF-mutated metastatic colorectal cancer with the combination of a BRAF inhibitor, cetuximab (Erbitux), and irinotecan, a randomized trial showed.

read article (free registration required)

Older Patients With GI Cancers Don't Always Receive Tx

(MedPage Today) Jan 22, 2017 - Older patients with esophageal or unresected gastric cancer benefited from treatment but often received no cancer-specific therapy, analyses of a large national database suggested.

read article (free registration required)

QoL Benefits with Palliative Surgery for Gastric Cancer

(MedPage Today) Jan 21, 2017 - Palliative surgery for gastric outlet obstruction allowed patients with incurable gastric cancer to resume oral food intake and improved quality of life (QoL) during the last months of life, Japanese investigators reported.

read article (free registration required)

Pamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers Symposium

(Yahoo! Finance) Jan 20, 2017 - FibroGen, Inc. today announced that updated results from an ongoing clinical study of pamrevlumab (FG-3019) in combination with standard-of-care chemotherapy in patients with locally advanced pancreatic ductal adenocarcinoma (PDAC) were presented in a poster session during the ASCO 2017 Gastrointestinal Cancers Symposium in San Francisco.

read article

Boston Biomedical Presents Clinical Data on First-in-Class Cancer Stemness Inhibitor Napabucasin at 2017 ASCO GI Symposium

(Yahoo! Finance) Jan 21, 2017 - Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stemness pathways, today presented data from two clinical studies for its lead investigational compound, napabucasin, at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco.

read article

ChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor CCX872 in Patients with Advanced Non-Resectable Pancreatic Cancer

(ChemoCentryx) Jan 20, 2017 - ChemoCentryx, Inc., today announced the presentation of results from its immuno-oncology program at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium being held January 19-21, 2017 in San Francisco, California.

read corporate press release

Opdivo (nivolumab) Demonstrated Efficacy and Improved Survival in Patients with Previously Treated Advanced Gastric Cancer in a Randomized Phase 3 Study

(BMS) Jan 19, 2017 - Opdivo demonstrated a 37% reduction in the risk of death compared to placebo; 12-month overall survival rates were 26.6% in Opdivo-treated patients compared to 10.9% in placebo-treated patients.

read corporate press release

2017 Symposium to Highlight Notable Research Advances in Gastrointestinal Cancers

(ASCO/2017 GI Cancers Symposium) Jan 18, 2017 - Six abstracts exploring key issues in the treatment of gastrointestinal cancers will be presented at the 2017 Gastrointestinal Cancers Symposium, taking place January 19-21 at the Moscone West Building in San Francisco.

read press release

PET Scans Can Inform and Improve Treatment for Patients With Esophageal Cancer

(ASCO/2017 GI Cancers Symposium) Jan 17, 2017 - Findings from a federally funded clinical trial point to a new way to improve the outlook for patients with esophageal cancer: using PET scans to assess tumor response to initial chemotherapy may allow doctors to tailor further chemotherapy.

read press release

PET Scans Can Inform and Improve Treatment for Patients With Esophageal Cancer

(UCCC/Colorado Cancer Blogs) Jan 17, 2017 - Findings from a federally funded clinical trial point to a new way to improve the outlook for patients with esophageal cancer: using PET scans to assess tumor response to initial chemotherapy may allow doctors to tailor further chemotherapy.

read article

Physical Activity Linked to Longer Survival in Advanced Colorectal Cancer

(ASCO/2017 GI Cancers Symposium) Jan 17, 2017 - A new analysis suggests that people with metastatic colorectal cancer who are more physically active fare better than those who are less active.

read press release

'Watch-and-Wait' Safe in Selected Rectal Cancer Patients

(Medscape Medical News) Jan 18, 2017 - New data support the "watch-and-wait" side of the ongoing debate about the best approach to treatment for patients with rectal cancer. With improved survival now being seen after initial chemoradiation, some experts are arguing for omitting surgery in lieu of observation.

read article (free registration required)

Watch-and-Wait Approach for Rectal Cancer Appears an Option for More Patients

(ASCO/2017 GI Cancers Symposium) Jan 17, 2017 - Real-world data from a large observational study suggests that omitting surgery in strictly selected patients with a clinical complete response does not compromise outcomes.

read press release

Moderate Exercise Can Improve Outcomes for Patients with Metastatic Colorectal Cancer, Study Shows

(Dana-Farber) Jan 17, 2017 - Patients with metastatic colorectal cancer may be able to lower the risk of the disease worsening, and improve their chances of survival, if they engage in moderate daily exercise, according to new research by investigators at Dana-Farber Cancer Institute.

read press release